Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.
Open accessThe DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS: Oral semaglutide was superior to placebo in reducing HbA1c (estimated treatment difference [ETD] –0.5% [95% CI –0.7, –0.3], –0.9% [–1.1, –0.7], and –1.2% [–1.4, –1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD −0.9 kg [95% CI −1.8, −0.0], −2.0 kg [−3.0, −1.0], and −3.3 kg [−4.2, −2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4–23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS: Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other phase 3 trials, no increase in hypoglycemia risk was observed versus comparator groups, including other GLP-1RAs (18–21, 23, 33–36).”
From Safety of Semaglutide (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated improved glycemic control and body weight loss without increasing the risk of hypoglycemia and reducing insulin requirements.[2][3][4][5][6]”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“For oral semaglutide, the placebo-controlled trials found nausea ranged between 5.1 and 23.2% (placebo 5.6–7.1%), vomiting between 2.9 and 9.9% (placebo 2.2–3.8%) and diarrhea between 5.1 and 15% (placebo 2.2–8%) during the on-treatment period (14, 17, 21).”
From Safety of Semaglutide (2021) · cites this paper as [21]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationStatistical Analysis with Missing Data
Bo., N., Little, R. J. A., & Rubin, D. B. (1988) · Population (French Edition) · doi:10.2307/1533221 · Cited by 2,095
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · cited 1×
“Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce HbA1c with a low risk of hypoglycemia and favorable effects on body weight (1,2).”
BackgroundSelf-citationPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Self-citationStatistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Cited by
Items 101–200 of 319
van Houtum, W. H., Schrömbges, P. P. G., Amadid, H., van Bon, A. C., Braae, U. C., Hoogstraten, C., & Herrings, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01588-5 · Cited by 24
“In PIONEER REAL Netherlands, adverse events with oral semaglutide were consistent with those observed in the PIONEER phase 3 RCTs. Reflective of the GLP-1RA class, gastrointestinal effects, including nausea, diarrhoea and vomiting, were the most common adverse events [12, 14–17, 29, 38].”
MethodResultInfluentialPratley, R. E., Crowley, M. J., Gislum, M., HERTZ, C. L., Jensen, T. B., Khunti, K., Mosenzon, O., & Buse, J. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00994-9 · Cited by 27
“Finally, in PIONEER 8, patients were randomised to oral semaglutide 3, 7 or 14 mg once daily or placebo as an add-on to basal, premixed or basal-bolus insulin with or without metformin [11].”
BackgroundMethodSelf-citationYabe, D., Deenadayalan, S., Horio, H., Kaneto, H., Jensen, T. B., Terauchi, Y., Yamada, Y., & Inagaki, N. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13764 · Cited by 23
Jiao, X., Peng, P., Zhang, Q., & Shen, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01319-x · Cited by 23
“Moreover, the leave-one-out sensitivity analysis revealed that excluding two studies (Seino et al. [25], Zinman et al. [32]) resulted”
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Tsukamoto, S., Tanaka, S., Yamada, T., Uneda, K., Azushima, K., Kinguchi, S., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15312 · Cited by 28
Singh, A. K., Singh, R., Singh, A., & Misra, A. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103024 · Cited by 22
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A., & Nogueira, J. P. (2024) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2024.03.012 · Cited by 22
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 27
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus
Clements, J. N., Isaacs, D. M., Hartman, R. E., & Gambill, K. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00951-6 · Cited by 22
Buse, J. B., Christensen, H. N., Harty, B. J., Mitchell, J., Soule, B. P., Zacherle, E. W., Cziraky, M. J., & Willey, V. J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003206 · Cited by 21
“9 23 However, the present study focuses on once-weekly subcutaneous semaglutide only.”
Self-citationCatrina, S., Amadid, H., Braae, U. C., Dereke, J., Ekberg, N. R., Klanger, B., & Jansson, S. P. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01614-6 · Cited by 22
“26064 211. consistent with other GLP‑1RAs, in partici‑ pants with T2D [9–15].”
BackgroundResultBain, E., & Bain, S. C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 21
“PIONEER 6 was the CVOT for oral semaglutide.(73) Key inclusion criteria were T2DM and increased cardiovascular risk defined as;”
MethodJensen, D. M., Skovsted, G. F., Bonde, M. F. B., Bentzon, J. F., Rolin, B., Franck, G., Ougaard, M. K., Voetmann, L. M., Bachmann, J. C., Uryga, A., et al. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.05.004 · Cited by 20
“Along these lines, treatment of VSMCs in vitro with GLP-1RAs has been proposed to modulate the expression of matrix metalloproteinases and inhibit VSMC proliferation and migration [12,13] and treatment with liraglutide reduced intima-media ratio in an atheroprone murine model [14], indicating that GLP-1RAs may influen…”
BackgroundInfluentialKurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Rudofsky, G., Amadid, H., Braae, U. C., Catrina, S., Kick, A., Mandavya, K., Roslind, K., Saravanan, P., van Houtum, W. H., & Jain, A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01668-6 · Cited by 22
Ishii, H., Hansen, B. B., Langer, J., & Horio, H. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00985-w · Cited by 19
Frazer, M., Swift, C., Gronroos, N. N., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., Noone, J. M., & Guevarra, M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02677-w · Cited by 19
“In clinical trials, patients with an oral semaglutide dose escalated to 14 mg for 26 weeks had a mean HbA1c decrease of 1.0–1.4% [12–17].”
InfluentialMeier, J. J., Granhall, C., Hövelmann, U., Navarria, A., Plum‐Mörschel, L., Ramesh, C. K., Tannapfel, A., & Kapitza, C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14632 · Cited by 19
Chae, Y., Kwon, S., Nam, J. H., Kang, E., Im, J., Kim, H.-J., & Lee, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2363838 · Cited by 18
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 20
Kalra, S., Das, S., & Zargar, A. H. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_522_21 · Cited by 24
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Chen, J., Zhang, Q., Wu, Q., Zhang, X., Xiang, Z., Zhu, S., Dai, T., & Si, Y.-X. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70151 · Cited by 17
Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A. D., Lanaras, L., Farajian, P., Galanakis, C., Georgantopoulos, G., Vlahos, N., Mastorakos, G. P., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090869 · Cited by 18
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
Saravanan, P., Bell, H. K., Braae, U. C., Collins, E., Deinega, A., Dhatariya, K., Machell, A., Trent, A., & Strzelecka, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02973-z · Cited by 16
“The safety and efficacy of oral semaglutide have been demonstrated across adult T2D populations with different ages, duration of diabetes, body mass index (BMI), baseline glycated haemoglobin (HbA 1C ) levels and races during the PIONEER clinical development programme [7–13].”
BackgroundInfluentialFiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16174 · Cited by 17
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Pinto, M., Brennan, L., Diehl, K., Lin, S., & Heacock, S. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241289959 · Cited by 18
“18,19 We found a baseline HbA 1C concentration of 8.5% associated with achieving an HbA 1C concentration of 7% in the oral and injectable semaglutide groups, respectively, at any time point during the study in exploratory analyses.”
InfluentialExploring beyond numeric weight loss: The metabolic effects of semaglutide
Sokary, S., & Bawadi, H. A. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.010 · Cited by 19
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants
Nielsen, M. S., Brøndsted, L., Kankam, M. K., Morelli, G., Nguyen, D., Skjøth, T. V., Patted, U. R. H., & van Hout, M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01674-8 · Cited by 15
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & SKOLNIK, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 17
Oral GLP1 Analog: Where Does the Tide Go?
Gardner, H. M., & Hamdy, O. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420984130 · Cited by 15
Self-citationWill oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
Seidu, S., Mellbin, L., Kaiser, M., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.07.011 · Cited by 14
Li, W. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500289 · Cited by 16
Chan, M. K., Dimitriou, A., & Lam, S. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000351 · Cited by 14
Eliasson, B., Ericsson, Å., Fridhammar, A., Nilsson, A., Persson, S., & Chubb, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00317-z · Cited by 14
A new opening for orally taken peptide drugs
Artursson, P., & Lundquist, P. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0513-1 · Cited by 14
Sadraei, S., Aarabi, A., Firouzabadi, S. R., Alinejadfard, M., Mohammadi, I., & Jolfayi, A. G. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05278-3 · Cited by 13
“Oral semaglutide also reduces systemic blood pressure, potentially reducing the incidence of MACE [43–45].”
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W. M., Lobo, M., Barbagelata, L., Cobo, A. L., & Nogueira, J. P. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.01.001 · Cited by 26
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Liu, Y., & Luo, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0873-2 · Cited by 15
Chu, L., Bradley, R., Auerbach, P., & Abitbol, A. (2024) · Diabetes, obesity and metabolism · doi:10.1111/dom.15834 · Cited by 11
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Suzuki, R., Amadid, H., Major‐Pedersen, A., & Yabe, D. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14219 · Cited by 12
Xie, P., Abildlund, M. T., Bækdal, T. A., He, X., Lyauk, Y. K., Patted, U. R. H., Zu, N., & Shi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15624 · Cited by 14
Candido, R., Loreto, C. D., Desenzani, P., Pantanetti, P., Romano, C., Settembrini, S., Solerte, S. B., & Fadini, G. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01625-3 · Cited by 14
Araki, E., Terauchi, Y., Watada, H., Deenadayalan, S., Christiansen, E., Horio, H., & Kadowaki, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14536 · Cited by 14
“Adverse events (AEs; including AEs leading to trial product discontinuation, and events of hypoglycaemia) were recorded descriptively from randomization up to the end of the trials (in-trial period).(8,10,11,15)”
BackgroundMethodResultSelf-citationPantanetti, P., Ronconi, V., Sguanci, M. E., Palomares, S. M., Mancin, S., Tartaglia, F. C., Cangelosi, G., & Petrelli, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164752 · Cited by 12
Wu, R., Xing, B., Huang, Y., Zhou, Z., Sun, B., Yu, L., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554795 · Cited by 11
Singh, A. K., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102436 · Cited by 13
Shabutdinova, O. R., Dautov, A. R., Samkov, A. A., Kononenko, A. V., Sargaliev, A. F., Davletshin, A. R., Andresova, P. A., Zarbeeva, K. R., Torshkhoeva, D. A., Rakhmonkulov, U. A., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13197 · Cited by 17
BALDASSARRE, M. P. A., Dalmazi, G. D., Coluzzi, S., Carrieri, F., Febo, F., Centorame, G., Cassino, P., Piacentino, L., Baroni, M. G., Consoli, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113054 · Cited by 13
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01201-z · Cited by 10
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting
Conti, M., Pontiggia, L., Vergani, M., Muraca, E., Cannistraci, R., Perra, S., Lattuada, G., Perseghin, G., & Ciardullo, S. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02424-9 · Cited by 12
“In PIONEER-6, the cardiovascular outcome trial (CVOT) of the programme, oral semaglutide treatment reached non-inferiority to placebo, showing a non-signifi - cant trend towards a lower incidence of first MACE and a significantly lower incidence of CV-related death and all-cause death [13– 19 ].”
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
“Addi - tionally, semaglutide improved fasting lipid profiles and led to slight increases in heart rate [55 ].”
Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations
Kim, D.-H., & Kim, J.-E. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00762-6 · Cited by 10
BBiomed, Z. L., Raveendran, D., Fourlanos, S., & Chong, E. W. T. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.12.022 · Cited by 10
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 10
Is polypharmacy the future for pharmacological management of obesity?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100322 · Cited by 12
Wu, T., Wong, C. K. H., Lui, D. T. W., Wong, S. K., Lam, C. L. K., Chung, M. S. H., McAllister, D., Welbourn, R., & Dixon, J. B. (2023) · BJS Open · doi:10.1093/bjsopen/zrad077 · Cited by 12
Chen, B., Tao, L., Tian, M., & Ji, Z. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.056 · Cited by 11
Wełnicki, M. T., Gorczyca-Głowacka, I., Mamcarz, A., Filipiak, K. J., Wożakowska−Kapłon, B., Barylski, M., Szymański, F. M., Kasprzak, J. D., Grabowski, M., & Dzida, G. J. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0282 · Cited by 15
Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis
Rebelo, T. G., de Araujo Paysano, M. L. B., Matheus, G. T. F. U., Ribeiro, D. M., Said, T. B., & Kelly, F. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133683 · Cited by 9
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Sillassen, C. D. B., Petersen, J. J., Faltermeier, P., Yucel, D., Siddiqui, F., Andersen, R. K., Graever, L., Bjerg, J. L., Kamp, C. B., Grand, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04486-0 · Cited by 10
“Non-serious adverse events were reported as outcomes in 45 trials [33–41, 43–46, 48–56, 58–67, 69–73, 75–79, 81, 82].”
Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus
Wesling, M., & D’Souza, J. J. (2022) · Drugs in Context · doi:10.7573/dic.2021-11-7 · Cited by 10
Berković, M. C., Režić, T., Bilić-Čurčić, I., & Mrzljak, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i20.6759 · Cited by 10
Dril, E. V., Allison, M., & Schumacher, C. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100163 · Cited by 11
“…controlled, parallel group trials have evaluated the addition of GLP-1 receptor agonists to intensive insulin regimens in patients with long-standing T2D (mean disease duration of 14 – 17 years) with a range of baseline insulin requirements and this literature is summarized in Table 1 [19 – 24].”
BackgroundMethodInfluentialMeier, J. J., Bardtrum, L., CHENG, A. Y. Y., Malling, B., Montanya, E., Wagner, L., & Pratley, R. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14957 · Cited by 9
“2% of patients treated with oral semaglutide experienced GI AEs, including nausea, diarrhoea or vomiting.(8-14) We sought to assess whether the body weight loss observed with oral semaglutide in the PIONEER trials was attributable to GI AEs.”
BackgroundOral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review
Sofogianni, A., & Τζιόμαλος, Κ. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01478-9 · Cited by 10
Nekidy, W. S. E., Hasan, H., Abidi, E., Sayegh, L. A., Dajani, R. Z., El-Kaissi, S., Hegazin, S. B., & Mallat, J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251340645 · Cited by 8
Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review
Zacharia, G. S., Gongati, S., Kharel, A., & Jacob, A. (2025) · Cureus · doi:10.7759/cureus.95632 · Cited by 10
“The PIONEER (Peptide InnOvatioN for Early diabEtes tReatment) trials confirmed the role of oral semaglutide in treating T2DM, leading to the US FDA approval of Rybelsus® in 2019 [17].”
Overgaard, R. V., Birkhan, O. A., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70769 · Cited by 9
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
Won, H., Cho, J., & Lee, S. (2025) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2025.33.e3 · Cited by 8
“PIONEER 5 (n = 822) [26], PIONEER 6 (n = 3,138) [27], and PIONEER 8 (n = 731) [28] targeted specific populations, including those with moderate renal impairment, cardiovascular risk factors, and insulin-treated patients, confirming efficacy and safety of oral semaglutide across various clinical…”
Dungan, K. M., Bardtrum, L., Christiansen, E., Eliasson, J., Mellbin, L., Woo, V. C., & Vilsbøll, T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01413-5 · Cited by 10
Self-citationEfficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis
Zhang, L., Hua, Z., Fang, Z., Wei, J., & Yang, L. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2483 · Cited by 12
“Six studies 14,17–19, 21, 22 reported changes in HbA1c compared to placebo, and statistical heterogeneity heterogeneity was Six studies 15–17, 20, 22, 23 reported a reduction in HbA1c compared to positive control drugs, FPG.”
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist
Powell, J., Piszczatoski, C., & Taylor, J. R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.017 · Cited by 8
A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
Selvarajan, R., & Subramanian, R. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s385196 · Cited by 8
“When added to insulin in the setting of poorly managed type 2 diabetes, oral semaglutide was superior to placebo in improving glycemic control and reducing body weight over 26 weeks, with significant improvements also found at 52 weeks and with no increase in the risk of hypoglycemia.(58) Both the Pioneer 9 and 10 stu…”
BackgroundZhang, Z., Li, A., Zheng, J., Liang, Y., Ma, L., & Su, L. (2025) · Endocrine Connections · doi:10.1530/ec-25-0205 · Cited by 8
“These events occurred at mild-to-moderate severity, primarily during the dose-escalation period, and decreased over time, especially after reaching the maintenance dose (33, 34, 35, 36).”
Giorgino, F., DʼSOUZA, S., Ludwig, L., Kiyosue, A., Ibriga, H., RHA, H., Denning, M., Wu, W.-S., Landó, L. F., & Tobian, J. A. (2026) · JAMA · doi:10.1001/jama.2026.9512 · Cited by 8
Self-citationBoye, K. S., Poon, J. L., Landó, L. F., Sapin, H., Huh, R., Wang, M., WILLIAMSON, S. E., & Patel, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01620-8 · Cited by 8
Bergman, B. K., Rosenstock, J., Garvey, W. T., Batterham, R. L., Chen, Y., Liu, M., Sharma, P., Karanikas, C. A., & Thieu, V. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16337 · Cited by 9
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
Manti, R., Cosmo, S. D., Desenzani, P., Ferrara, L., Girelli, A., Memoli, G., Bisio, A., Braae, U. C., Deinega, A., Berra, C., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01719-6 · Cited by 9
“Overall, the safety profile of oral sema-glutide was consistent with the well-established GLP-1RA profile, including once-weekly subcutaneous semaglutide [7–12].”
InfluentialSelf-citationElangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Joshi, S., Rajput, R., Chowdhury, S., Singh, A. K., Bantwal, G., Das, A. K., Unnikrishnan, A., Saboo, B., Kesavadev, J., Ghosal, S., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102508 · Cited by 8
Self-citationPharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
“Complementary to this, the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) program assessed oral semaglutide in phase 3a trials, comparing it to placebo and other glucose-lowering agents [46–50 , 60–67].”
Costa, S., Miranda, C., Elefante, A., Vallone, V., Vinci, C., Borroni, F., Brandoni, G., Labate, A. M. M., Pomo, F. L., & Strazzabosco, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16314 · Cited by 7
“18 28 The drug was found to be safe and effective in reducing glycated haemoglobin (HbA1c) and, in a dose-dependent manner, body weight, 19 – 28 demonstrating superiority compared with placebo 19,22,23,26,27 and other active comparators.”
Mohammed, O., & Kelemu, T. (2025) · Health Science Reports · doi:10.1002/hsr2.71065 · Cited by 6
“Gastrointestinal adverse effects such as nausea, vomiting, and diarrhea are common with all GLP ‐ 1 receptor agonists and are typically mild to moderate in severity in patients with type 2 diabetes mellitus (T2DM) [136, 137].”
Samuels, S. L., Chajecki, A., Hu, P., Kayser, M., Weyman, K., Pan, B., Brown, E. A., Name, M. A. V., & Wolf, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15430 · Cited by 6
“29 We similarly showed a decrease in insulin use in this cohort, with the proportion of patients prescribed basal and prandial insulin decreasing between baseline and follow-up visits.”
BackgroundHui, B. T. K., Yeong, J. L., Pető, T., & Willoughby, C. E. (2024) · Peptides · doi:10.1016/j.peptides.2024.171240 · Cited by 6
Lv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6
Bissonnette, R., Eichenfield, L. F., Simpson, E. L., Thaçi, D., Kabashima, K., Thyssen, J. P., Guttman‐Yassky, E., Nunes, F. P., Gamalo, M., Ahmad, F., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18881 · Cited by 7
Fazioli, K., Rind, D. M., Guzauskas, G. F., Hansen, R. N., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1072 · Cited by 7
He, M., Deng, M., Wang, J., Fan, P., Wang, Y., Zhao, X., He, Y., Shi, B., & Sui, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9649 · Cited by 6
Oral semaglutide: the innovation in type 2 diabetes management
Shestakova, M. V., Шамхалова, М. Ш., Galstyan, G. R., Ruyatkina, L. A., & Суплотова, Л. А. (2021) · Diabetes Mellitus · doi:10.14341/dm12790 · Cited by 6
Metadata
- Authors
- Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, Zinman, B., Fikry, S., Bajaj, H., Landry, D., Caplan, D., Woo, V., Harris, S., Thuan, J.-F., Serusclat, P., Cariou, B., Gourdy, P., Fradet, G., Monier, A., Borot, S., Monguillon, P., Gouet, D., Doupis, J., Tentolouris, N., Tsimichodimos, V., Melidonis, A., Bekiari, E., Bargiota, A., Agarwal, S., Saboo, B., Chatterjee, S., Mohan, V., Shaikh, S., Gupta, Y., Bhattacharyya, A., Manikath, N., Jain, S., Sasaki, T., Osonoi, T., Fukuda, S., Wada, S., Kiyosue, A., Ide, Y., Onishi, Y., Matoba, K., Takai, K., Yamauchi, A., Inoue, S., Kaneko, S., Ikeda, H., Ohta, Y., Hisatomi, A., Senokuchi, T., Jinnouchi, H., Nakamura, S., Soto, J. R. L., Briones, I. R., Bogdanski, P., Szyprowska, E., Modzelewska, A., Wozniak, I., Zyangirova, S., Sergeeva-Kondrachenko, M., Davis, T., Thomson, S., Frias, J., Gandy, W., Lingvay, I., Pounds, K., Bowman-Stroud, C., Dempsey, M., Huffman, D., Ahmed, A., Fraser, N., Ortiz-Carrasquillo, R., Bolster, D. E., Adams, M., Hummel, M., Free, A., Houser, P., Shockey, G., Barnum, O., Bhasker, K., Cornett, G., Streja, D., Kirby, W., Lynd, S., Folkerth, S., Nakhle, S., Norwood, P., Perez, R., Snyder, B., Farris, N., Litchfield, W., Hamdy, O., Park, J., Aroda, V., & Buse, J.
- Affiliations
- Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- University of North Carolina at Chapel Hill (US)
- Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
- Novo Nordisk A/S, Søborg, Denmark
- Novo Nordisk (Denmark) (DK)
- Kumamoto University (JP)
- ORCID
- Aroda, Vanita R.
- Buse, John B.
- Harris, Stewart B.
- Araki, Eiichi
- Bajaj, Harpreet
- Woo, Vincent
- Gourdy, Pierre
- Borot, Sophie
- Bekiari, Eleni
- Saboo, Banshi
- Chatterjee, Sanjay
- Mohan, Viswanathan
- Shaikh, Shehla
- Gupta, Yashdeep
- Bhattacharyya, Arpandev
- Sasaki, Takashi
- Osonoi, Takeshi
- Kiyosue, Arihiro
- Onishi, Yukiko
- Kaneko, Shizuka
- Ikeda, Hiroki
- Ohta, Yasuharu
- Senokuchi, Takafumi
- Jinnouchi, Hideaki
- Nakamura, Shuji
- Lingvay, Ildiko
- Norwood, Paul
- Hamdy, Osama
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-07-10
- Volume
- 42
- Issue
- 12
- Pages
- 2262-2271
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7364672
- OpenAlex
- W2974714926
- Semantic Scholar
- dfcdee292cee0de5fee471e8d85a78bf385a1d29
- Cited by
- 300
- References
- 37
- Citations by year
- 2026: 28 · 2025: 62 · 2024: 51 · 2023: 32 · 2022: 39 · 2021: 43 · 2020: 41 · 2019: 3
- FWCI
- 25.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Diabetes Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- MannKind Corporation
- Kowa Company
- Zafgen
- Boehringer Ingelheim Japan
- Eisai
- Novo Nordisk (U54-DK-118612, UC4-DK-108612, UL1-TR-002489)
- Astellas Pharma
- Shionogi
- Terumo
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- National Institutes of Health (UL1TR002489, UL1-TR-)
- Japan Society for the Promotion of Science (17H04201, 18K08482)
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK108612, U01DK098246, U54DK118612)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, insulin, metformin, glycemic control, HbA1c, weight loss, nausea, GLP-1 receptor agonists, treatment policy estimand, dose-dependent effects, uncontrolled diabetes, adverse events, tolerability, rescue medication, treatment discontinuation
- MeSH terms
- Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Nausea, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.